IL226397B - Bifunctional molecules with antibody-mobilizing and fusion-inhibiting activity against human immunodeficiency virus - Google Patents

Bifunctional molecules with antibody-mobilizing and fusion-inhibiting activity against human immunodeficiency virus

Info

Publication number
IL226397B
IL226397B IL226397A IL22639713A IL226397B IL 226397 B IL226397 B IL 226397B IL 226397 A IL226397 A IL 226397A IL 22639713 A IL22639713 A IL 22639713A IL 226397 B IL226397 B IL 226397B
Authority
IL
Israel
Prior art keywords
recruiting
antibody
inhibitory activity
activity against
immunodeficiency virus
Prior art date
Application number
IL226397A
Other languages
English (en)
Hebrew (he)
Other versions
IL226397A0 (en
Original Assignee
Univ Yale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Yale filed Critical Univ Yale
Publication of IL226397A0 publication Critical patent/IL226397A0/en
Publication of IL226397B publication Critical patent/IL226397B/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL226397A 2010-11-18 2013-05-16 Bifunctional molecules with antibody-mobilizing and fusion-inhibiting activity against human immunodeficiency virus IL226397B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41497710P 2010-11-18 2010-11-18
US201161522518P 2011-08-11 2011-08-11
PCT/US2011/061174 WO2012068366A2 (fr) 2010-11-18 2011-11-17 Molécules bifonctionnelles dotées d'une activité de recrutement d'anticorps et d'inhibition de l'entrée du virus dirigées contre le virus de l'immunodéficience humaine

Publications (2)

Publication Number Publication Date
IL226397A0 IL226397A0 (en) 2013-07-31
IL226397B true IL226397B (en) 2018-02-28

Family

ID=46084646

Family Applications (1)

Application Number Title Priority Date Filing Date
IL226397A IL226397B (en) 2010-11-18 2013-05-16 Bifunctional molecules with antibody-mobilizing and fusion-inhibiting activity against human immunodeficiency virus

Country Status (16)

Country Link
US (5) US9562038B2 (fr)
EP (1) EP2640720B1 (fr)
JP (2) JP6155193B2 (fr)
KR (1) KR20140000275A (fr)
CN (2) CN107011333B (fr)
AU (1) AU2011329829B2 (fr)
BR (1) BR112013012309A2 (fr)
CA (1) CA2818308A1 (fr)
CL (1) CL2013001429A1 (fr)
CO (1) CO6801635A2 (fr)
EA (1) EA201390726A1 (fr)
IL (1) IL226397B (fr)
MX (1) MX350974B (fr)
PE (1) PE20140406A1 (fr)
SG (2) SG190829A1 (fr)
WO (1) WO2012068366A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20030329A1 (es) 2001-08-08 2003-05-12 Takeda Chemical Industries Ltd Compuesto biciclico con actividad antagonista de ccr5 y produccion del mismo
WO2011046946A2 (fr) * 2009-10-13 2011-04-21 Yale University Molécules bifonctionnelles à activité de recrutement d'anticorps et d'inhibition d'entrée dirigées contre le virus de l'immunodéficience humaine
JP6155193B2 (ja) 2010-11-18 2017-06-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ ヒト免疫不全ウイルスに対する抗体動員及び進入阻害活性を有する二官能性分子
US20140308342A1 (en) 2011-11-11 2014-10-16 Yale University Reprogramming urokinase into an antibody-recruiting anticancer agent
EP4005600A1 (fr) 2012-04-26 2022-06-01 Yale University Molécule de délivrance de médicament sous forme cytotoxique ciblant le vih (cdm-h), activité cytotoxique contre le virus de l'immunodéficience humaine et leurs méthodes d'utilisation
WO2013166110A1 (fr) 2012-05-02 2013-11-07 Yale University Molécules de recrutement d'anticorps conjugués à un agoniste de tlr)
JP6473138B2 (ja) 2013-05-03 2019-02-20 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ 癌、特に前立腺癌を標的とする合成抗体模倣化合物（ＳｙＡＭ）
CA2971093A1 (fr) * 2014-12-23 2016-06-30 Tobira Therapeutics, Inc. Procede de preparation de cenicriviroc et d'analogues apparentes
WO2017023994A1 (fr) 2015-08-06 2017-02-09 Yale University Composés de recrutement d'anticorps à base de petites molécules pour le traitement du cancer
LT3390441T (lt) 2015-12-15 2021-11-10 Gilead Sciences, Inc. Žmogaus imunodeficito virusą neutralizuojantys antikūnai
US20190151464A1 (en) * 2016-03-18 2019-05-23 Rutgers, The State University Of New Jersey Targeting tumor cells with chemotherapeutic agents conjugated to anti-matriptase antibodies by in vivo cleavable linking moieties
US10407411B2 (en) 2016-06-21 2019-09-10 Tobira Therapeutics, Inc. Purified cenicriviroc and purified intermediates for making cenicriviroc
WO2018026997A1 (fr) 2016-08-03 2018-02-08 Yale University Molécules de recrutement d'anticorps pour le traitement du cancer
WO2018045043A1 (fr) 2016-08-31 2018-03-08 Tobira Therapeutics, Inc. Formes solides de mésylate de cenicriviroc et procédés de fabrication de formes solides de mésylate de cenicriviroc
CN107056762B (zh) * 2016-12-22 2020-08-28 四川百利药业有限责任公司 一种用作抗流感病毒的双羰基类似物
JP7009517B2 (ja) 2017-06-21 2022-01-25 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖ ｇｐ１２０およびｃｄ３を標的とする多重特異性抗体
WO2021151391A1 (fr) * 2020-01-30 2021-08-05 沈阳福洋医药科技有限公司 Application du composé isovalérylspiramycine et sa composition pour la préparation d'un médicament antiviral
CN111995622B (zh) * 2020-08-20 2022-04-15 复旦大学 化合物及其用途

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
ZA893284B (en) * 1988-05-04 1990-03-28 Igen Inc Peptide analogs and their use as haptens to elicit catalytic antibodies
ATE210464T1 (de) * 1992-06-09 2001-12-15 Neorx Corp BIOTIN-DOTA KONJUGATE UND DEREN VERWENDUNG IN ßPRETARGETINGß VERFAHREN
JP3319073B2 (ja) * 1993-08-24 2002-08-26 和光純薬工業株式会社 免疫学的測定方法
US6140505A (en) * 1995-03-10 2000-10-31 G. D. Searle & Co. Synthesis of benzo fused heterocyclic sulfonyl chlorides
US6469006B1 (en) * 1999-06-15 2002-10-22 Bristol-Myers Squibb Company Antiviral indoleoxoacetyl piperazine derivatives
US6573262B2 (en) * 2000-07-10 2003-06-03 Bristol-Myers Sqibb Company Composition and antiviral activity of substituted indoleoxoacetic piperazine derivatives
DE60113543T2 (de) * 2000-07-10 2006-07-13 Bristol-Myers Squibb Co. Zusammensetzung und antivirale wirkung von substituierten indol-oxo-aceto-piperidin-derivaten
US6825201B2 (en) * 2001-04-25 2004-11-30 Bristol-Myers Squibb Company Indole, azaindole and related heterocyclic amidopiperazine derivatives
HUP0401523A3 (en) * 2004-07-29 2007-05-02 Richter Gedeon Vegyeszet Indole-2-carboxamide derivatives, pharmaceutical compositions containing them and process for producing them
EP3564674B1 (fr) * 2006-11-01 2021-08-25 Ventana Medical Systems, Inc. Haptènes, conjugués de haptènes, leurs compositions et leur procédé de préparation et d'utilisation
PL2291659T3 (pl) * 2008-05-13 2016-04-29 Univ Yale Małe cząsteczki chimerowe do rekrutacji przeciwciał do komórek nowotworowych
WO2010008519A2 (fr) * 2008-07-14 2010-01-21 Andrew Metters Marqueurs diagnostiques in vitro comprenant des nanoparticules de carbone et trousses
EP2395992A2 (fr) * 2009-02-10 2011-12-21 The Scripps Research Institute Vaccination programmée chimiquement
WO2011046946A2 (fr) 2009-10-13 2011-04-21 Yale University Molécules bifonctionnelles à activité de recrutement d'anticorps et d'inhibition d'entrée dirigées contre le virus de l'immunodéficience humaine
US8450361B2 (en) * 2010-08-06 2013-05-28 Bristol-Myers Squibb Company Substituted indole and azaindole oxoacetyl piperazinamide derivatives
JP6155193B2 (ja) 2010-11-18 2017-06-28 イェール ユニバーシティーＹａｌｅ Ｕｎｉｖｅｒｓｉｔｙ ヒト免疫不全ウイルスに対する抗体動員及び進入阻害活性を有する二官能性分子

Also Published As

Publication number Publication date
CN103402998A (zh) 2013-11-20
US20200392121A1 (en) 2020-12-17
JP6155193B2 (ja) 2017-06-28
MX2013005462A (es) 2014-02-03
KR20140000275A (ko) 2014-01-02
BR112013012309A2 (pt) 2016-08-23
US20130245040A1 (en) 2013-09-19
US10703743B2 (en) 2020-07-07
US11136316B2 (en) 2021-10-05
PE20140406A1 (es) 2014-04-16
WO2012068366A3 (fr) 2012-11-15
EA201390726A1 (ru) 2014-06-30
EP2640720A4 (fr) 2014-05-28
CO6801635A2 (es) 2013-11-29
US20190002447A1 (en) 2019-01-03
JP2017052776A (ja) 2017-03-16
SG10201510402WA (en) 2016-01-28
IL226397A0 (en) 2013-07-31
EP2640720B1 (fr) 2018-10-17
CN107011333B (zh) 2021-03-19
CN103402998B (zh) 2017-09-26
JP2013543003A (ja) 2013-11-28
US20170096415A1 (en) 2017-04-06
CL2013001429A1 (es) 2014-04-11
CN107011333A (zh) 2017-08-04
AU2011329829B2 (en) 2017-02-09
US9562038B2 (en) 2017-02-07
EP2640720A2 (fr) 2013-09-25
WO2012068366A2 (fr) 2012-05-24
CA2818308A1 (fr) 2012-05-24
WO2012068366A9 (fr) 2013-07-18
US10030008B2 (en) 2018-07-24
US11858917B2 (en) 2024-01-02
SG190829A1 (en) 2013-07-31
AU2011329829A1 (en) 2013-07-11
MX350974B (es) 2017-09-27
US20220089579A1 (en) 2022-03-24
JP6567486B2 (ja) 2019-08-28

Similar Documents

Publication Publication Date Title
IL226397A0 (en) Bi-functional molecules with antibody recruitment and inhibition activity
IL252398A0 (en) cd37-binding molecules and their immunoconjugates
IT1402653B1 (it) Composito fotocatalizzatore e prodotto funzionale fotocatalitico usante lo stesso.
EP2799540A4 (fr) Arginase humaine et arginase humaine pégylée, et leur application
EP2712384A4 (fr) Élément de coupe novateur et structure de coupe le mettant en uvre
ME02672B (fr) Phényl-3-aza-bicyclo[3.1.0]hex-3-yl-méthanones et leur utilisation en tant que médicament
HK1187527A1 (en) N-carboxyalkyl auristatins and the use thereof
ZA201209595B (en) N-acetyl-dl-leucine, neuroprotective and retinoprotective medicament
EP2771008A4 (fr) Macrocycles augmentant l'activité p53 et leurs utilisations
IL222835A0 (en) Bifunictional molecules for inactivating hiv and blocking hiv entry
PL2855506T3 (pl) Peptydy i ich zastosowanie
ZA201207416B (en) Cdca5 peptides and vaccines including the same
EP2636737A4 (fr) Facteur contrôlant la couleur de la peau et des cheveux
EP2515939A4 (fr) Virus inactivé sous l'effet de la lumière, systèmes et procédés d'utilisation de ceux-ci
EP2646546A4 (fr) Peptides tomm34 et vaccins les comprenant
EP2659891A4 (fr) Médicament ayant une activité contre la famille des herpès-virus
IL221474A0 (en) Hjurp peptides and vaccines including the same
GB201012941D0 (en) Determining the extent of a structure on or in the skin of a subject
HK1213978A1 (zh) 流感病毒和 型糖尿病
EP2630238A4 (fr) Peptides wdhd1 et vaccins les contenant
EP2630237A4 (fr) Peptides c18orf54 et vaccins les contenant
TWM390691U (en) Caster device and luggage having the caster device
PT2356993T (pt) Medicamento para a redução da colesterolemia e da trigliceridemia
GB201015789D0 (en) Peptides and their use in the treatment
ZA201205434B (en) Coffins, sarcophagi, cinerary urns and the like

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed